Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...

Note: not an actual photo of Robin A personalised central serous chorioretinopathy treatment by London consultant ophthalmi ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Newsweek, in partnership with Statista, is proud to announce the sixth edition of America’s Best Physical Rehabilitation Centers, recognizing 320 leading inpatient facilities across the United States.